Teva Pharmaceutical Industries News and Activities

Teva Pharmaceutical Industries is one of the...

• Forbes Global 2000 (#989);
• TOB Iconic 10,000.

Teva Pharmaceutical Industries is a company listed under the stock ticker TEVA (IL).

Teva Pharmaceutical Industries has a direct presence in 18 countries.

Teva Pharmaceutical Industries has 19 subsidiaries including Medis Germany, Pliva and Tapi.

Acquisition, funding and merger involving Teva Pharmaceutical Industries.

• Teva Pharmaceutical Industries has announced the acquisition of Emalex Biosciences  (posted on April 30 2026).

View the org chart displaying its 147 main executives

Most searched biographies at Teva Pharmaceutical Industries

• Richard Francis, Director, President and Chief Executive Officer
• Perry Nisen, Director
• Sol Barer, Chairman of the Board

Popular executive movements at Teva Pharmaceutical Industries

• Deanne Kissinger has joined the company as Chief Talent Officer  (posted on January 19 2026).

Create your alert
to follow the executive moves at Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott
• Jonathan Leff - Director at Larimar Therapeutics

Learn more about the Pharmaceuticals industry

Press releases by Teva Pharmaceutical Industries

• The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acti
• Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
• Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are
• Teva to Present at the BofA Securities Health Care Conference
• Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
• Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
• Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Me
• Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schi
• Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at F
• Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Accep
• View more press releases Close

Social media about Teva Pharmaceutical Industries

• Teva Pharmaceutical Industries on Wikipedia, Google News & Yahoo Finance
• Teva Pharmaceutical Industries on LinkedIn, X (Twitter) & YouTube